Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 1,540 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CAO Ryan Bartolucci sold 1,540 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $97,050.80. Following the sale, the chief accounting officer directly owned 59,264 shares in the company, valued at $3,734,817.28. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Down 6.3%

NASDAQ TEM opened at $59.61 on Friday. The company has a debt-to-equity ratio of 2.70, a quick ratio of 2.48 and a current ratio of 2.61. The company has a market capitalization of $10.87 billion, a P/E ratio of -56.24 and a beta of 3.61. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $89.09. The stock has a 50 day moving average price of $72.89 and a 200-day moving average price of $57.56.

Tempus AI (NASDAQ:TEM – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The firm had revenue of $411.54 million during the quarter, compared to analyst estimates of $409.39 million. During the same period last year, the firm posted ($0.46) earnings per share. Tempus AI’s revenue for the quarter was up 23.1% compared to the same quarter last year. As a group, equities analysts predict that Tempus AI, Inc. will post -1.20 EPS for the current fiscal year.

Key Tempus AI News

These are some of the TEM news items that stood out recently:

  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, signaling confidence in Tempus AI’s outlook. HC Wainwright ratings
  • Positive Sentiment: Tempus plans to present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The presentations could raise the visibility of its research and precision-medicine platform, though the article provides no study results. Tempus to present 16 abstracts
  • Positive Sentiment: Tempus extended its strategic collaboration with AstraZeneca. Recent investor coverage also cited data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027, offering potential support for future growth. AstraZeneca collaboration extension Investor takeaways

Hedge Funds Weigh In On Tempus AI

Large investors have recently modified their holdings of the stock. PCM Encore LLC bought a new stake in Tempus AI in the third quarter worth $201,000. Advisors Asset Management Inc. purchased a new position in Tempus AI during the third quarter worth $3,977,000. Integrated Wealth Concepts LLC boosted its stake in Tempus AI by 44.3% during the third quarter. Integrated Wealth Concepts LLC now owns 3,618 shares of the company’s stock worth $296,000 after buying an additional 1,110 shares during the period. Schwarz Investment Partners Inc. bought a new position in Tempus AI during the third quarter valued at $109,000. Finally, New York State Common Retirement Fund increased its position in Tempus AI by 3.0% during the third quarter. New York State Common Retirement Fund now owns 54,400 shares of the company’s stock valued at $4,455,000 after acquiring an additional 1,600 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on TEM. JPMorgan Chase & Co. lifted their price objective on shares of Tempus AI from $45.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 14th. Needham & Company LLC boosted their target price on shares of Tempus AI from $75.00 to $89.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Roth Capital assumed coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price on the stock. BTIG Research increased their price target on shares of Tempus AI from $80.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Finally, Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Eleven analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $79.37.

Check Out Our Latest Analysis on TEM

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Recommended Stories

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.